ArticleNature communications2016
A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours.
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 89 citations in OpenAlex.
- Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment.Trends in biotechnology · 2026Review
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
- A biohybrid platform integrating bacterial propulsion and photoresponsive nanomedicine for adequate intratumoral drug delivery.Journal of nanobiotechnology · 2026Article
- New insights into the effects of microbiome and its derived metabolites on targeted immunotherapy.Journal of the Egyptian National Cancer Institute · 2025Review
- The interplay between gut bacteria and targeted therapies: implications for future cancer treatments.Molecular medicine (Cambridge, Mass.) · 2025Review
- Extraction, Purification, Characterization, Applications of Chitosan, Plant Gum Polysaccharides, and Other Polysaccharides: A Review.Scientifica · 2025Review
- Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy.Journal of nanobiotechnology · 2024Review
- Bacterial carrier-mediated drug delivery systems: a promising strategy in cancer therapy.Frontiers in bioengineering and biotechnology · 2024Review
- Article
- Active carbon based supercapacitors with Au colloids: the case of placing the colloids in close proximity to the electrode interface.Nanoscale advances · 2022Article
- Clinical Significance of Lipid Transport Function of ABC Transporters in the Innate Immune System.Membranes · 2022Review
- Review
- Recombinant AttenuatedCancers · 2022Review
- Nucleic Acid-Based Nanobiosensor (NAB) Used forNanomaterials (Basel, Switzerland) · 2022Review
- Engineered microorganism-based delivery systems for targeted cancer therapy: a narrative review.Biomaterials translational · 2022Review
- Gut microbiota regulation of P-glycoprotein in the intestinal epithelium in maintenance of homeostasis.Microbiome · 2021Article
- Integration ofCancers · 2021Review
- Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor.Asian journal of pharmaceutical sciences · 2021Review
- Application of machine learning in prediction of Chemotherapy resistant of Ovarian Cancer based on Gut Microbiota.Journal of Cancer · 2021Article
- Perspectives on OncolyticFrontiers in immunology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Salmonella enterica serotype Typhimurium is a food-borne pathogen that also selectively grows in tumours and functionally decreases P-glycoprotein (P-gp), a multidrug resistance transporter. Here we report that the Salmonella type III secretion effector, SipA, is responsible for P-gp modulation through a pathway involving caspase-3. Mimicking the ability of Salmonella to reverse multidrug resistance, we constructed a gold nanoparticle system packaged with a SipA corona, and found this bacterial mimic not only accumulates in tumours but also reduces P-gp at a SipA dose significantly lower than free SipA. Moreover, the Salmonella nanoparticle mimic suppresses tumour growth with a concomitant reduction in P-gp when used with an existing chemotherapeutic drug (that is, doxorubicin). On the basis of our finding that the SipA Salmonella effector is fundamental for functionally decreasing P-gp, we engineered a nanoparticle mimic that both overcomes multidrug resistance in cancer cells and increases tumour sensitivity to conventional chemotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.